NCT01969747View on ClinicalTrials.gov

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Empagliflozin medium placebo

Empagliflozin medium placebo

DRUG

Empagliflozin low placebo

Empagliflozin low placebo

DRUG

Empagliflozin low placebo

Empagliflozin low placebo

DRUG

Empagliflozin high placebo

Empagliflozin high placebo

DRUG

Empagliflozin medium

Empagliflozin medium

DRUG

Empagliflozin medium placebo

Empagliflozin medium placebo

DRUG

Empagliflozin high placebo

Empagliflozin high placebo

DRUG

Empagliflozin high placebo

Empagliflozin high placebo

DRUG

Empagliflozin medium placebo

Empagliflozin medium placebo

DRUG

Empagliflozin low placebo

Empagliflozin low placebo

DRUG

Empagliflozin low

Empagliflozin low

DRUG

Empagliflozin high

Empagliflozin high

Trial Locations (2)

Unknown

1245.78.43001 Boehringer Ingelheim Investigational Site, Graz

1245.78.49001 Boehringer Ingelheim Investigational Site, Neuss

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01969747 - Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days | Biotech Hunter | Biotech Hunter